Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Teva Pharmaceutical has reported net sales of $3.8 billion for the fourth quarter of 2009 compared to $2.8 billion in 2008, an increase of 33%. For the full year net sales were $13.9 billion, 25% increase compared to $11 billion in 2008.
Subscribe to our email newsletter
Quarterly non-GAAP net income was $847m, an increase of 28% compared to same period an year ago. Annual non-GAAP net income $3 billion, an increase of 22% compared same period in 2008.
Quarterly non-GAAP operating income was $1.0 billion, up 41% compared with the fourth quarter of 2008. Quarterly GAAP operating income totaled $412m, compared with a loss of $412m.
Teva’s annual non-GAAP operating income was $3.9 billion, up 35%. Annual GAAP operating income totaled $2.4 billion, compared with $1.1 billion.
Shlomo Yanai, president and chief executive officer of Teva, said: “2009 was a very good year for Teva, a year in which our company delivered record-breaking sales and profits across all our geographies and major businesses.
“This was also a year of major strategic achievements, including the successful integration of Barr, a process which was completed less than a year after closing, and from which we expect to continue to derive significant synergies for many years to come.
“I believe that especially against the backdrop of a troubled world economy, our results this year demonstrate Teva’s agility and the strength of our balanced business model, which enable us to deliver continuous profitable growth year after year.”